erlotinib hydrochloride has been researched along with tak 285 in 1 studies
| Studies (erlotinib hydrochloride) | Trials (erlotinib hydrochloride) | Recent Studies (post-2010) (erlotinib hydrochloride) | Studies (tak 285) | Trials (tak 285) | Recent Studies (post-2010) (tak 285) |
|---|---|---|---|---|---|
| 4,353 | 786 | 3,033 | 26 | 2 | 25 |
| Protein | Taxonomy | erlotinib hydrochloride (IC50) | tak 285 (IC50) |
|---|---|---|---|
| Chain A, Epidermal growth factor receptor | Homo sapiens (human) | 0.023 | |
| Chain A, Receptor tyrosine-protein kinase erbB-2 | Homo sapiens (human) | 0.023 | |
| Chain A, Receptor tyrosine-protein kinase erbB-2 | Homo sapiens (human) | 0.017 | |
| Epidermal growth factor receptor | Homo sapiens (human) | 1.6902 | |
| Receptor tyrosine-protein kinase erbB-2 | Homo sapiens (human) | 0.0138 | |
| Tyrosine-protein kinase Lck | Homo sapiens (human) | 2.4 | |
| Tyrosine-protein kinase Lyn | Homo sapiens (human) | 5.2 | |
| Hepatocyte growth factor receptor | Homo sapiens (human) | 4.2 | |
| Receptor tyrosine-protein kinase erbB-3 | Homo sapiens (human) | 0.023 | |
| Tyrosine-protein kinase CSK | Homo sapiens (human) | 4.7 | |
| Dual specificity mitogen-activated protein kinase kinase 1 | Homo sapiens (human) | 1.1 | |
| Dual specificity mitogen-activated protein kinase kinase 5 | Homo sapiens (human) | 5.7 | |
| Receptor tyrosine-protein kinase erbB-4 | Homo sapiens (human) | 0.1415 | |
| Aurora kinase B | Homo sapiens (human) | 1.7 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ding, X; Li, Y; Mao, W; Meng, X; Tang, H; Wang, X; Xie, S; Yang, H | 1 |
1 other study(ies) available for erlotinib hydrochloride and tak 285
| Article | Year |
|---|---|
Drug response to HER2 gatekeeper T798M mutation in HER2-positive breast cancer.
Topics: Antineoplastic Agents; Breast Neoplasms; Bridged Bicyclo Compounds, Heterocyclic; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Hydroxybutyrates; Lapatinib; Molecular Dynamics Simulation; Mutation; Protein Kinase Inhibitors; Purines; Quinazolines; Receptor, ErbB-2; Staurosporine | 2016 |